About: COVID-19 Vaccine: A comprehensive status report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Vaccine: A comprehensive status report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 Vaccine: A comprehensive status report
Creator	Gupta, Vandana Affiliations, Vandana Kaur, Simran
Source	Elsevier; Medline; PMC
abstract	The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigation mostly on SARS-CoV and to extent on MERS has taught lessons to vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2020.198114
bibo:pmid	32800805
has license	no-cc
sha1sum (hex)	3c31b1dd002899846b274e39ae27424b1d7c1ea7
schema:url	https://doi.org/10.1016/j.virusres.2020.198114
resource representing a document's title	COVID-19 Vaccine: A comprehensive status report
has PubMed Central identifier	PMC7423510
has PubMed identifier	32800805
schema:publication	Virus Res
resource representing a document's body	covid:3c31b1dd002899846b274e39ae27424b1d7c1ea7#body_text
is schema:about of	named entity 'INCLUDE' named entity 'MONOCLONAL ANTIBODIES' named entity 'PATHOGENESIS' named entity 'HUMAN HEALTH' named entity 'DEDICATED' named entity 'BUT' named entity 'OVERVIEW' named entity 'VARIOUS' named entity 'REACTIVITY' named entity 'vaccines' named entity 'pathogenesis' named entity 'healthcare workers' named entity 'monoclonal antibodies' named entity 'passive immunization' named entity 'China' named entity 'COVID-19 pandemic' named entity 'WHO' named entity 'comprehensive status' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'human cytomegalovirus' named entity 'antiviral' named entity 'trimerization' named entity 'vaccine' named entity 'vaccine' named entity 'zoonotic transmission' named entity 'nasal cannula' named entity 'insertional mutagenesis' named entity 'intramuscular injections' named entity 'University of Oxford' named entity 'adjuvants' named entity 'vaccine' named entity 'postfusion' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'antibody' named entity 'protein' named entity 'COVID-19' named entity 'vaccine' named entity 'vaccine' named entity 'clinical trials' named entity 'clinical trials' named entity 'virus' named entity 'protein' named entity 'adaptive immune response' named entity 'peptide vaccines' named entity 'vaccine' named entity 'SARS-CoV-2' named entity 'mRNA' named entity 'immunogenicity' named entity 'vaccine' named entity 'coronavirus' named entity 'Cytotoxic T cells' named entity 'Dengue' named entity 'endosome' named entity 'live attenuated' named entity 'vaccine' named entity 'anti-tumor' named entity 'ssRNA' named entity 'virus' named entity 'genome' named entity 'CD8+ T cells' named entity 'infection' named entity 'Israel Institute for Biological Research' named entity 'protease' named entity 'spike protein' named entity 'Zonula Occludens-1' named entity 'mRNA' named entity 'cytotoxic T cells' named entity 'Protein' named entity 'mutation' named entity 'Receptor Binding Domain' named entity 'humoral immunity' named entity 'influenza virus' named entity 'BamHI' named entity 'GSK' named entity 'Phase 1/2' named entity 'CD8+ T cells' named entity 'antiviral therapy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software